Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Imb Dx Inc. operates in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions, indicating a steady level of prosecution activity. These actions are distributed across 3 distinct examiners, which means that the workload is spread among multiple individuals at the patent office.
The busiest examiner identified for this portfolio is HAYES, JONATHAN EDWARD, who is responsible for 1 pending office action. Because the total number of pending actions is 3 and there are 3 distinct examiners, HAYES, JONATHAN EDWARD handles the same number of actions as the other examiners. This lack of examiner concentration requires practitioners to manage multiple separate examiner relationships simultaneously.
Despite the involvement of 3 distinct examiners, all prosecution activity is contained within 1 distinct art unit. This indicates that while the examiners differ, the technical focus of the Biotechnology & Pharmaceuticals innovations remains within a single administrative division. Practitioners can benefit from a consistent set of art unit guidelines, even as they adapt their arguments to the individual styles of the assigned examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAYES, JONATHAN EDWARD | 1 | 36.4% | +20.7% |
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| NGUYEN, PETER | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 28d overdue |
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | — |
| 18025529 | METHOD OF IDENTIFYING FALSE POSITIVE VARIANTS IN NUCLEIC ACID SEQUENCING | NGUYEN, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 28d overdue |
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18027792 | METHOD FOR PREPARATION OF MULTI-ANALYTICAL PREDICTION MODEL FOR CANCER DIAGNOSIS | HAYES, JONATHAN EDWARD | — | §101§103§112 | Non-Final OA | — | Pending | Mar 22, 2023 |
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | SALMON, KATHERINE D | 1682 | §101§102§112 | Final Rejection | 28d overdue | Pending | Mar 21, 2023 |
| 18025529 | METHOD OF IDENTIFYING FALSE POSITIVE VARIANTS IN NUCLEIC ACID SEQUENCING | NGUYEN, PETER | — | §101§103§112 | Non-Final OA | — | Pending | Mar 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial